Clinical Infectious Diseases

Papers
(The H4-Index of Clinical Infectious Diseases is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Withdrawn as duplicate: Cover image/text496
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms461
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary423
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With an Indoor Music Event That Required Proof of Full Vaccination Against Coronavirus Disease 2019 (COVID-19) Prio409
In the Literature401
Reply to Focosi et al395
Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial386
Acute Appendicitis of Unexpected Etiology267
Redefining Complicated Coagulase-Negative Staphylococcal Bacteremia257
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C246
Blood Culture Time to Positivity and Risk of Infective Endocarditis235
A Point-of-Care Prediction Tool for Recurrent Tuberculosis170
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptas150
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial147
Correction to: Prevalence of Ocular Complications in Candidemia: Defining the “Battlefield”138
Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?137
Corrigendum to: A New Specimen for Syphilis Diagnosis: Evidence by High Loads ofTreponema pallidumDNA in Saliva132
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 201127
Eyes Wide Shut: A Cohort Study Questioning the Role of Fundoscopy in Infective Endocarditis Diagnosis126
Response to Rezahosseini and Barrella Harboe123
Association of Virus Variation and Vaccination Status With Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection122
T-SPOT.TB Reactivity in Southern African Children With and Without in Utero Human Immunodeficiency Virus Exposure118
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza?116
Susceptibility to Human Immunodeficiency Virus Type 1 Acquisition Linked to Malaria Exposure: A Case-Control Study115
Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)114
Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patie114
Response to ‘Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome’111
Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants111
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acineto109
Correction to: Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Val109
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity104
Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021104
Does “Toxoplasma Abscess” Properly Describe Brain Lesions Caused by Toxoplasma gondii?103
Don’t Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C102
Lessons I Learned from Our Soldier101
Invasive Listeriosis in Southern Switzerland: A Local Problem That Is Actually Global100
Pre-exposure Prophylaxis for Transgender People: A Systematic Review98
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment96
Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study95
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis95
Go V.I.R.A.L.: Social Media Engagement Strategies in Infectious Diseases94
Are Contact Precautions “Essential” for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?93
Clinical Presentation, Antimicrobial Resistance, and Treatment Outcomes of Aeromonas Human Infections: A 14-Year Retrospective Study and Comparative Genomics of 2 Isolates From Fatal Cases89
Point-of-care Ultrasound in Infectious Diseases: Current Insights and Future Perspectives87
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study87
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial86
CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?86
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?84
Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 202183
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States83
State-of-the-Art Review: Neurosyphilis82
Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave81
Development of a Machine Learning Modeling Tool for Predicting HIV Incidence Using Public Health Data From a County in the Southern United States80
Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947–201979
A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic Shock79
Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa79
Daily Second-generation Integrase Strand Inhibitors and Short-course Tuberculosis Preventive Therapy: What More Do We Need to Know?78
Revisiting REVISIT: The Case for Ceftazidime/Avibactam Plus Aztreonam77
Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption76
Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021–August 202276
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial76
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial75
Correction to: Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa75
Considerations on the Associations Between Antiretroviral Regimen and Changes in Blood Pressure in the D2EFT Study75
Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores74
Predictors of Mortality of Streptococcal Bacteremia and the Role of Infectious Diseases Consultation: A Retrospective Cohort Study72
Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination71
Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis70
Characterizing the Rise of Disseminated Gonococcal Infections in California, July 2020–July 202168
Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus68
0.53517389297485